Published in J Clin Oncol on September 01, 2000
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer (2006) 1.85
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol (2009) 1.80
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res (2013) 1.62
Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J (2010) 1.60
The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res (2010) 1.54
Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med (2007) 1.53
Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience. BMC Cancer (2015) 1.48
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One (2015) 1.44
Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer. Br J Cancer (2011) 1.44
Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17). Br J Cancer (2014) 1.44
The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis (2000) 1.39
Surgical resection of urological tumor metastases following medical treatment. Dtsch Arztebl Int (2012) 1.34
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs (2006) 1.29
CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res (2011) 1.28
Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma (2010) 1.25
Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. Curr Oncol (2013) 1.23
A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer (2004) 1.21
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol (2016) 1.12
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer (2009) 1.12
miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics (2012) 1.08
Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J (2009) 1.08
Phase II study of everolimus in metastatic urothelial cancer. BJU Int (2013) 1.07
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. Clin Exp Nephrol (2012) 1.06
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer (2013) 1.05
Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Int J Clin Oncol (2012) 1.02
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst (2013) 1.00
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer (2013) 1.00
Medical paternalism and expensive unsubsidised drugs. BMJ (2005) 1.00
Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther (2013) 0.98
Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Ther Adv Urol (2015) 0.98
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol (2013) 0.97
The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int (2010) 0.97
A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res (2011) 0.97
Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol (2013) 0.96
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol (2008) 0.96
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer (2006) 0.96
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer (2008) 0.96
First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol (2011) 0.96
YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene (2015) 0.96
Gemcitabine eliminates double minute chromosomes from human ovarian cancer cells. PLoS One (2013) 0.94
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs (2011) 0.94
Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. Eur Urol (2011) 0.93
1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer (2010) 0.92
Urothelial carcinomas: a focus on human epidermal receptors signaling. Am J Transl Res (2011) 0.92
Clinical states model for biomarkers in bladder cancer. Future Oncol (2009) 0.92
Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging (2015) 0.91
Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm (2012) 0.91
Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther (2011) 0.90
Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol (2008) 0.90
Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer. BMC Cancer (2011) 0.90
Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: Case report and literature review. Surg Neurol Int (2012) 0.90
Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Can Urol Assoc J (2009) 0.89
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs (2010) 0.89
Progress in personalizing chemotherapy for bladder cancer. Adv Urol (2012) 0.89
Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia (2011) 0.89
2-methoxyestradiol induces mitotic arrest, apoptosis, and synergistic cytotoxicity with arsenic trioxide in human urothelial carcinoma cells. PLoS One (2013) 0.88
Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. Int J Clin Oncol (2010) 0.87
Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. Can Urol Assoc J (2014) 0.87
Long-term survival after adrenalectomy for asynchronous metastasis of bladder cancer to the bilateral adrenal glands. Case Rep Urol (2012) 0.87
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol (2012) 0.87
Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells. PLoS One (2012) 0.86
Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev (2009) 0.86
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs (2006) 0.85
Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma. BMC Cancer (2012) 0.85
The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells. BMC Cancer (2014) 0.85
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw (2016) 0.85
MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. PLoS One (2015) 0.84
Adjuvant chemotherapy after radical cystectomy for bladder cancer: a comparative study using inverse-probability-of-treatment weighting. J Cancer Res Clin Oncol (2014) 0.84
Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature. Can Urol Assoc J (2010) 0.84
Carcinomatous meningitis: the natural history of successfully treated metastatic bladder cancer. Case Rep Oncol (2011) 0.84
Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment. Int J Clin Oncol (2012) 0.84
Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells. Oncol Lett (2013) 0.84
Rapid fatal outcome from pulmonary arteries compression in transitional cell carcinoma. J Oncol (2010) 0.84
Immunotherapy for urothelial carcinoma: current status and perspectives. Cancers (Basel) (2011) 0.83
The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen. Int J Clin Oncol (2011) 0.83
Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis. Cancer Chemother Pharmacol (2012) 0.83
The role of chemotherapy in upper tract urothelial carcinoma. Adv Urol (2009) 0.83
Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Mar Drugs (2009) 0.83
Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress. Oncotarget (2015) 0.83
Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia (2007) 0.83
A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett (2012) 0.83
Chemotherapy for bladder cancer in patients with impaired renal function. Nat Rev Urol (2011) 0.83
Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches. Front Pharmacol (2013) 0.82
Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer (2005) 0.82
Systemic therapy for bladder cancer - a medical oncologist's perspective. J Solid Tumors (2014) 0.82
Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma. Int J Clin Oncol (2013) 0.82
Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer. Oncologist (2013) 0.82
Gemcitabine and cisplatin for advanced, metastatic bladder cancer. J Clin Oncol (2001) 0.82
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. Invest New Drugs (2008) 0.82
Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer. BMC Cancer (2015) 0.81
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med (2000) 18.12
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. EMBO J (2000) 7.54
The DNA sequence and comparative analysis of human chromosome 20. Nature (2002) 7.40
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38
The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. EMBO J (2001) 5.69
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Traction forces generated by locomoting keratocytes. J Cell Biol (1994) 4.97
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet (1991) 4.31
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Pre-mRNA splicing alters mRNP composition: evidence for stable association of proteins at exon-exon junctions. Genes Dev (2000) 3.74
Imaging the traction stresses exerted by locomoting cells with the elastic substratum method. Biophys J (1996) 3.63
Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J Exp Med (1990) 3.01
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med (1998) 2.85
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Branch nucleophile selection in pre-mRNA splicing: evidence for the bulged duplex model. Genes Dev (1994) 2.63
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest (2006) 2.53
Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer (1987) 2.50
Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer (1999) 2.26
Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol (1999) 2.25
Baseline staging tests in primary breast cancer: a practice guideline. CMAJ (2001) 2.22
Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ (1997) 2.21
Eye contact and face scanning in early infancy. Science (1977) 2.20
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1999) 2.19
Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol (1985) 2.18
Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med (1989) 2.15
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A (1998) 2.11
Structure of the detoxification catalyst mercuric ion reductase from Bacillus sp. strain RC607. Nature (1991) 2.01
Organ sparing surgery for malignant germ cell tumor of the testis. J Urol (2001) 1.99
Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst (1994) 1.92
Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer (1999) 1.91
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem (1999) 1.89
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol (2001) 1.89
Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev (2000) 1.89
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol (2012) 1.87
The human Prp8 protein is a component of both U2- and U12-dependent spliceosomes. RNA (1999) 1.81
Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer (1989) 1.80
Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial) Ann Oncol (2000) 1.80
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol (2000) 1.76
Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer (1996) 1.76
The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol (2007) 1.76
Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer (1996) 1.75
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer (2005) 1.75
Precursor RNAs harboring nonsense codons accumulate near the site of transcription. Mol Cell (2001) 1.72
Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer (1997) 1.72
Bimolecular exon ligation by the human spliceosome. Science (1997) 1.72
The C-terminal region of hPrp8 interacts with the conserved GU dinucleotide at the 5' splice site. RNA (1999) 1.71
Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med (2000) 1.67
Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer (2004) 1.64
Use of a site-directed triple mutant to trap intermediates: demonstration that the flavin C(4a)-thiol adduct and reduced flavin are kinetically competent intermediates in mercuric ion reductase. Biochemistry (1990) 1.63
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol (1993) 1.60
SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer (1997) 1.60
Deadly diving? Physiological and behavioural management of decompression stress in diving mammals. Proc Biol Sci (2011) 1.57
Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol (2007) 1.55
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1997) 1.54
Linkage of susceptibility to experimental allergic encephalomyelitis to the major histocompatibility locus in the rat. J Exp Med (1973) 1.53
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol (2003) 1.52
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer (2007) 1.52
Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol (2001) 1.50
Intravenous diazepam in the treatment of prolonged seizure activity. N Engl J Med (1967) 1.50
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1995) 1.49
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann Oncol (2011) 1.48
The obstacles to maximising the impact of public access defibrillation: an assessment of the dispatch mechanism for out-of-hospital cardiac arrest. Heart (2007) 1.46
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol (2008) 1.44
Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology (1995) 1.43
Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer (1977) 1.43
Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor. Bone Marrow Transplant (1992) 1.42
Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial. Heart (2007) 1.42
Ondansetron in the control of refractory emesis following radiotherapy. Clin Oncol (R Coll Radiol) (1992) 1.40
Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res (1984) 1.40
Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res (2001) 1.39
[Experimentation with Di Bella polychemotherapy in Tuscany]. Epidemiol Prev (2001) 1.39
Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer (1996) 1.39
[Prostate cancer centres / prostate centres--certified by DKG or DVPZ]. Aktuelle Urol (2009) 1.39
Intron recognition comes of AGe. Nat Struct Biol (2000) 1.38
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A (2000) 1.36
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol (2003) 1.35
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology (2005) 1.34
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res (2001) 1.33
Biometric analyses of normal skeletal muscle. Acta Neuropathol (1971) 1.31
Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. Eur Radiol (2013) 1.30
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
Drinking and schooling. J Health Econ (1993) 1.24